Abionyx jumps on positive trial results in therapy for septic patients

Abionyx Pharma SA

07/04/2022 08:42

** Shares in Abionyx Pharma  ABNX.PA  jump 8.4% after the
biopharmaceutical group reported positive interim results in the
clinical trial of its CER-001 therapy for septic patients at
high risk of acute kidney injury  urn:newsml:reuters.com:*:nFWN2W50B5
    ** The group says CER-001 rapidly improved biomarkers of
inflammation, preventing septic patients' decline into acute
kidney injury
    ** "The promising interim results of this Phase 2a study
confirm that CER-001 could potentially fill a void that exists
in treating sepsis and other severe, acute inflammatory
diseases," CEO Cyrille Tupin says
    ** "Although this publication is only a step in this phase
IIa study, the initial results bode well for the continuation of
the process" - MidCap Partners

 (Reporting by Diana Mandiá)
 ((diana.mandiaalvarez@thomsonreuters.com))